Date: 2016-04-20
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Curis (USA - MA) Aurigene (India)
Product: CA-4948
Action
mechanism: kinase inhibitor. CA-4948 is an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4). Curis has exclusive licenses to CA-4948 under a collaboration agreement with Aurigene established in 2015.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 20, 2016, Curis and its collaborator, Aurigene, presented data on CA-4948, the lead compound from the interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor program. The Aurigene presentation "Efficacy and safety of highly selective novel IRAK4 inhibitors for treatment of ABC-DLBCL" provided a detailed profile of the pharmacologic and biologic properties of the lead molecule, CA-4948. This compound has favorable drug metabolism as well as pharmacokinetics properties and appears to have a clean in vitro toxicity profile. CA-4948 showed potent anti-tumor activity in vivo in two models of MYD88 mutant- DLBCL disease. CA-4948 also had potent anti-inflammatory effects in a rodent model of inflammation suggesting the potential use of an IRAK4 inhibitor in both cancer and inflammatory diseases.
